Author Archives for Adeline Chauvigné

BIOREGATE FORUM: A GREAT SUCCESS!

In September in Nantes, an International Forum dedicated to regenerative medicine was held, bringing together 180 participants. Based on the... View Article

Rédigé par Adeline Chauvigné, le 2016-10-10

BIOREGATE FORUM: A GREAT SUCCESS!

In September in Nantes, an International Forum dedicated to regenerative medicine was held, bringing together 180 participants. Based on the... View Article

Horama raises €4 million with Omnes Capital, Sham Innovation Santé and GO Capital

Horama raises €4 million with Omnes Capital, Sham Innovation Santé and GO Capital Proceeds from this fundraising will be used to:... View Article

Rédigé par Adeline Chauvigné, le 2016-07-20

Horama raises €4 million with Omnes Capital, Sham Innovation Santé and GO Capital

Horama raises €4 million with Omnes Capital, Sham Innovation Santé and GO Capital Proceeds from this fundraising will be used to:... View Article

OSE Immunotherapeutics : exercise of option within global license agreement with Janssen

OSE Immunotherapeutics announces exercise of option within global license agreement with Janssen for further clinical development of FR104 and potential commercialisation... View Article

OGD2 Pharma and Green Cross LabCell start collaboration

OGD2 Pharma and Green Cross LabCell start collaboration for developing NKcell therapeutics targeting the O-acetyl-GD2 cancer antigen Nantes France & Seoul... View Article

Rédigé par Adeline Chauvigné, le 2016-07-20

OGD2 Pharma and Green Cross LabCell start collaboration

OGD2 Pharma and Green Cross LabCell start collaboration for developing NKcell therapeutics targeting the O-acetyl-GD2 cancer antigen Nantes France & Seoul... View Article

Affilogic enters into a Research Collaboration and Licensing Agreement with Sanofi on Nanofitin-conjugated biotherapeutics

Affilogic announces the signature of a collaboration and license agreement with Sanofi for the development of Nanofitin®-conjugated biotherapeutics. Nantes –... View Article

Rédigé par Adeline Chauvigné, le 2016-07-04

Affilogic enters into a Research Collaboration and Licensing Agreement with Sanofi on Nanofitin-conjugated biotherapeutics

Affilogic announces the signature of a collaboration and license agreement with Sanofi for the development of Nanofitin®-conjugated biotherapeutics. Nantes –... View Article

Biofortis is pleased to announce its cooperation with Triskelion

Biofortis and Triskelion are pleased to announce the partnership signed between Biofortis, the innovation Center of Mérieux Nutrisciences, and Triskelion,... View Article

Rédigé par Adeline Chauvigné, le 2016-06-30

Biofortis is pleased to announce its cooperation with Triskelion

Biofortis and Triskelion are pleased to announce the partnership signed between Biofortis, the innovation Center of Mérieux Nutrisciences, and Triskelion,... View Article

Maryvonne Hiance Chairman of France Biotech

  Atlanpole Biotherapies is pleased to announce  the election of one of its iconic entrepreneur : Maryvonne Hiance, who is... View Article

Rédigé par Adeline Chauvigné, le 2016-07-20

Maryvonne Hiance Chairman of France Biotech

  Atlanpole Biotherapies is pleased to announce  the election of one of its iconic entrepreneur : Maryvonne Hiance, who is... View Article

Research Summer School

The University of Angers is very pleased to announce the Summer Schools Angers 2016. From 27th June to 8th July,... View Article

CESTI IHU: INNOVATION TOWARDS IMMUNE SYSTEM MODULATION

  CESTI IHU: towards an innovative therapy aiming at modulating the immune system The research program led by Prof. Karin... View Article

Rédigé par Adeline Chauvigné, le 2016-06-20

CESTI IHU: INNOVATION TOWARDS IMMUNE SYSTEM MODULATION

  CESTI IHU: towards an innovative therapy aiming at modulating the immune system The research program led by Prof. Karin... View Article

XENOTHERA closes a new capital increase above 2 million euros

XENOTHERA, a young biotech who develops an innovative immunosuppressant, has closed on June 2nd, 2016, a second fundraising for more... View Article

Rédigé par Adeline Chauvigné, le 2016-06-17

XENOTHERA closes a new capital increase above 2 million euros

XENOTHERA, a young biotech who develops an innovative immunosuppressant, has closed on June 2nd, 2016, a second fundraising for more... View Article